Cyclerion Appoints Regina Graul, Ph.D., as President
December 04, 2023 08:00 ET
|
Cyclerion Therapeutics, Inc.
– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy – – Peter Hecht,...
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
November 30, 2023 18:16 ET
|
Cyclerion Therapeutics, Inc.
- Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in...
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
July 31, 2023 07:00 ET
|
Cyclerion Therapeutics, Inc.
– Asset Purchase Agreement Closed; Cyclerion Received Equity Ownership in Tisento and Upfront Cash Payment – – Tisento Developing Zagociguat in MELAS*, a Rare Primary Mitochondrial Disease...
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement
June 01, 2023 16:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (“Cyclerion” or the “Company”) (Nasdaq: CYCN) today announced that it has received a formal notice from The Nasdaq...
Cyclerion Announces Reverse Stock Split
May 15, 2023 13:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (the “Company”, “Cyclerion Therapeutics”, “Cyclerion”) (Nasdaq: CYCN) announced today that it will effect a reverse...
Cyclerion Announces Corporate Updates and Q1 2023 Financial Results
May 11, 2023 18:00 ET
|
Cyclerion Therapeutics, Inc.
Definitive agreement reached with new company (“NewCo”) established by certain Cyclerion shareholders and new investors Cyclerion to receive $8M in cash and 10% equity in NewCo in exchange for its...
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018
May 11, 2023 18:00 ET
|
Cyclerion Therapeutics, Inc.
Certain Cyclerion shareholders and new investors have agreed to invest $81M to launch a new company targeting diseases of mitochondrial dysfunction Cyclerion to receive $8M in cash and 10% equity in...
Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement
April 03, 2023 07:30 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that the Board of Directors of the Company, acting solely by all of its independent...
Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases
March 27, 2023 07:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments for serious diseases,...
Cyclerion Reports Corporate Update and Full Year 2022 Financial Results
March 22, 2023 16:40 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced corporate updates including advances in its zagociguat (formerly CY6463)...